Our goal is to understand how nutrient-responsive signaling pathways can be harnessed to promote health and longevity. Rapamycin, an inhibitor of the protein kinase mTOR, can improve both health and longevity in model organisms including mammals. Understanding and manipulating the mTOR signaling pathway through dietary, pharmaceutical or genetic interventions may provide insight into the treatment of age-related diseases, including diabetes, Alzheimer’s disease, cancer, and Hutchinson-Gilford Progeria Syndrome.
- Dietary Interventions in Aging and Age-Related Disease
- Biology of Aging and mTOR
- Rapamcyin and rapalogs
The Lamming lab is supported in part by the NIH National Institute on Aging and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Other recent sources of support include the American Federation For Aging Research, the Glenn Foundation for Medical Research, the Progeria Research Foundation, and the Wisconsin Partnership Program.
Postdoctoral, Ph.D. students, M.D. students and undergraduates interested in pursuing research in the Lamming lab should contact Dr. Lamming directly at email@example.com.
Isoleucine is an essential amino acid which, in excess, counters the health benefits of the mTOR longevity pathway. The @LammingLab is reporting that an isoleucine-restricted diet extends the lifespan of mice by 33% 👏 @Cell_Metabolism pic.twitter.com/rGKHVCgjPI— David Sinclair (@davidasinclair) November 9, 2023
Congratulations to graduate student @mariahcalubag, whose paper on "FGF21 Has a Sex-Specific Role in Calorie-Restriction-Induced Beiging of White Adipose Tissue in Mice" is now offically out in the first ever issue of Aging Biology! https://t.co/i5u0P7mm6Q pic.twitter.com/MJ3hrTxM0X— Lamming Lab (@LammingLab) July 5, 2023
May the #rapamycin be with you! Pleased to be able to announce our new review on "Targeting the biology of aging with #mTOR inhibitors" with @MannickJoan now available at @NatureAging. Free-to-read link now available at https://t.co/8cdajcZjCF pic.twitter.com/mMIxCWAx0Y— Lamming Lab (@LammingLab) May 4, 2023